Lancet Digital Health study of 1.7 million records shows 10-year risk of serious statin myopathy exceeds 10% in just 0.04% of users

Researchers analyzed Clinical Practice Research Datalink records for 1.7 million adults aged 50-plus in England from 1998-2018, building sex-specific models that predicted 1-, 5-, and 10-year risks of statin-associated myopathy while accounting for competing mortality. Fewer than 0.04% of participants had a 10-year absolute risk above 10%, confirming earlier meta-analyses that placed rhabdomyolysis incidence near 1-3 per 100,000 person-years. The observational design cannot exclude residual confounding from unmeasured frailty or concurrent medications yet supplies individualized risk estimates absent from prior aggregate data. For the millions prescribed statins, the fear of severe muscle damage is largely unfounded as risks remain under 1% over a decade, a message that can shift adherence decisions within months. Future randomized trials that embed these risk calculators into prescribing interfaces are needed to test whether personalized numbers increase persistence and reduce cardiovascular events.